Literature DB >> 28449447

Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI.

Yusuke Okuma1, Yukio Hosomi1.   

Abstract

Entities:  

Year:  2017        PMID： 28449447      PMCID： PMC5394089          DOI： 10.21037/jtd.2017.03.26

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  23 in total

1.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

2.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

3.  Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.

Authors:  Shintaro Kanda; Hidehito Horinouchi; Yutaka Fujiwara; Hiroshi Nokihara; Noboru Yamamoto; Ikuo Sekine; Hideo Kunitoh; Kaoru Kubota; Tomohide Tamura; Yuichiro Ohe
Journal:  Lung Cancer       Date:  2015-07-02       Impact factor: 5.705

4.  Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

Authors:  David Jackman; William Pao; Gregory J Riely; Jeffrey A Engelman; Mark G Kris; Pasi A Jänne; Thomas Lynch; Bruce E Johnson; Vincent A Miller
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

5.  Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

Authors:  Takashi Seto; Terufumi Kato; Makoto Nishio; Koichi Goto; Shinji Atagi; Yukio Hosomi; Noboru Yamamoto; Toyoaki Hida; Makoto Maemondo; Kazuhiko Nakagawa; Seisuke Nagase; Isamu Okamoto; Takeharu Yamanaka; Kosei Tajima; Ryosuke Harada; Masahiro Fukuoka; Nobuyuki Yamamoto
Journal:  Lancet Oncol       Date:  2014-08-27       Impact factor: 41.316

6.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Authors:  Masahiro Fukuoka; Seiji Yano; Giuseppe Giaccone; Tomohide Tamura; Kazuhiko Nakagawa; Jean-Yves Douillard; Yutaka Nishiwaki; Johan Vansteenkiste; Shinzoh Kudoh; Danny Rischin; Richard Eek; Takeshi Horai; Kazumasa Noda; Ichiro Takata; Egbert Smit; Steven Averbuch; Angela Macleod; Andrea Feyereislova; Rui-Ping Dong; José Baselga
Journal:  J Clin Oncol       Date:  2003-05-14       Impact factor: 44.544

7.  Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

Authors:  Yi-Long Wu; Jin Soo Lee; Sumitra Thongprasert; Chong-Jen Yu; Li Zhang; Guia Ladrera; Vichien Srimuninnimit; Virote Sriuranpong; Jennifer Sandoval-Tan; Yunzhong Zhu; Meilin Liao; Caicun Zhou; Hongming Pan; Victor Lee; Yuh-Min Chen; Yan Sun; Benjamin Margono; Fatima Fuerte; Gee-Chen Chang; Kasan Seetalarom; Jie Wang; Ashley Cheng; Elisna Syahruddin; Xiaoping Qian; James Ho; Johan Kurnianda; Hsingjin Eugene Liu; Kate Jin; Matt Truman; Ilze Bara; Tony Mok
Journal:  Lancet Oncol       Date:  2013-06-17       Impact factor: 41.316

8.  Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

Authors:  Geoffrey R Oxnard; Kenneth S Thress; Ryan S Alden; Rachael Lawrance; Cloud P Paweletz; Mireille Cantarini; James Chih-Hsin Yang; J Carl Barrett; Pasi A Jänne
Journal:  J Clin Oncol       Date:  2016-06-27       Impact factor: 44.544

9.  EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.

Authors:  D Planchard; Y Loriot; F André; A Gobert; N Auger; L Lacroix; J C Soria
Journal:  Ann Oncol       Date:  2015-08-12       Impact factor: 32.976

10.  Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.

Authors:  M Schuler; J C-H Yang; K Park; J-H Kim; J Bennouna; Y-M Chen; C Chouaid; F De Marinis; J-F Feng; F Grossi; D-W Kim; X Liu; S Lu; J Strausz; Y Vinnyk; R Wiewrodt; C Zhou; B Wang; V K Chand; D Planchard
Journal:  Ann Oncol       Date:  2015-12-08       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.